Therapy, Toxics and drugs

• MG132
  22 April 2010

  MG132 is a proteasome inhibitor.
  References
  MG132, a proteasome inhibitor, induced death of calf pulmonary artery endothelial cells via caspase-dependent apoptosis and GSH depletion. Han YH, Moon HJ, You BR, Yang YM, Kim SZ, Kim SH, Park WH. Anticancer Res. 2010 Mar;30(3):879-85. PMID: #"20393010#
  MG132, a proteasome inhibitor, attenuates pressure-overload-induced cardiac hypertrophy in rats by modulation of mitogen-activated protein kinase signals. Chen B, Ma Y, Meng R, Xiong Z, Zhang (...)

• epigenetic drugs
  19 April 2010

  Epigenetics is central to our understanding of the dynamic and adaptive nature of cancer cell phenotypes that cannot be explained by the constraints of genetic alterations.
  DNA methylation and histone modifications are the best characterized of the different layers of epigenetic dysregulation of human tumors.
  Both sets of epigenetic marks may also affect DNA sequences that give rise to
  microRNAs. The first epigenetic drugs, such as DNA demethylating agents and histone deacetylase (...)

• artificial miRNA
  9 March 2010

  artificial microRNA

• AZD6244
  4 March 2010

  ARRY-142886

• MEK1/2 inhibitors
  4 March 2010

  References
  The First-in-Human Study of the Hydrogen Sulfate (Hyd-Sulfate) Capsule of the MEK1/2 Inhibitor AZD6244 (ARRY-142886): A Phase I Open-Label Multicenter Trial in Patients with Advanced Cancer. Banerji U, Camidge DR, Verheul HM, Agarwal R, Sarker D, Kaye SB, Desar IM, Timmer-Bonte JN, Eckhardt SG, Lewis KD, Brown KH, Cantarini MV, Morris C, George SM, Smith PD, van Herpen CM. Clin Cancer Res. 2010 Mar 1;16(5):1613-23. PMID: (...)

• ALK inhibitors
  3 February 2010

  The anaplastic lymphoma kinase (ALK) is a validated target for the therapy of different malignancies.
  Aberrant expression of constitutively active ALK chimeric proteins has been implicated in the pathogenesis of anaplastic large-cell lymphoma (ALCL) and has been detected in other cancers such as inflammatory myofibroblastic tumors, diffuse large B-cell lymphomas, certain non-small-cell lung cancers, rhabdomyosarcomas, neuroblastomas and glioblastomas.
  crizotinib (PF-02341066 or PF-1066) (...)

• multikinase inhibitors
  3 February 2010

  References
  Antitumor activity of pyridoisoquinoline derivatives F91873 and F91874, novel multikinase inhibitors with activity against the anaplastic lymphoma kinase. Kruczynski A, Mayer P, Marchand A, Vispé S, Fournier E, Annereau JP, Brel V, Barret JM, Delsol G, Imbert T, Fahy J, Bailly C. Anticancer Drugs. 2009 Jun;20(5):364-72. PMID: #19322071#

• translation targeting
  29 January 2010

  References
  Targeting translation in acute myeloid leukemia: a new paradigm for therapy? Tamburini J, Green AS, Chapuis N, Bardet V, Lacombe C, Mayeux P, Bouscary D. Cell Cycle. 2009 Dec;8(23):3893-9. PMID: #19934662#

• diazoxide
  27 January 2010

  References
  Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy. Yildizdas D, Erdem S, Küçükosmanoglu O, Yilmaz M, Yüksel B. Adv Ther. 2008 May;25(5):515-9. PMID: #18512033#

• diazoxide
  27 January 2010

  References
  Pulmonary hypertension, heart failure and neutropenia due to diazoxide therapy. Yildizdas D, Erdem S, Küçükosmanoglu O, Yilmaz M, Yüksel B. Adv Ther. 2008 May;25(5):515-9. PMID: #18512033#

0 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | ... | 170